BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 147] [Article Influence: 131.0] [Reference Citation Analysis]
Number Citing Articles
1 Shen YC, Hsu HC, Lin TM, Chang YS, Hu LF, Chen LF, Lin SH, Kuo PI, Chen WS, Lin YC, Chen JH, Liang YC, Chang CC. H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. J Clin Oncol 2022;:JCO2101802. [PMID: 35044851 DOI: 10.1200/JCO.21.01802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Yin L, Zhou L, Xu R. Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Front Mol Biosci 2020;7:599142. [PMID: 33681288 DOI: 10.3389/fmolb.2020.599142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yoshio S, Kanto T. Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunol Med 2021;44:175-86. [PMID: 33444517 DOI: 10.1080/25785826.2020.1868664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Sun Y, He Y, Tong J, Liu D, Zhang H, He T, Bi Y. All-trans retinoic acid inhibits the malignant behaviors of hepatocarcinoma cells by regulating ferroptosis. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.04.011] [Reference Citation Analysis]
5 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li X, Wu S, Yu Y. Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies. Front Med (Lausanne) 2020;7:569759. [PMID: 33490093 DOI: 10.3389/fmed.2020.569759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yu CL, Yu YL, Yang SF, Hsu CE, Lin CL, Hsieh YH, Chiou HL. Praeruptorin A reduces metastasis of human hepatocellular carcinoma cells by targeting ERK/MMP1 signaling pathway. Environ Toxicol 2021;36:540-9. [PMID: 33226171 DOI: 10.1002/tox.23059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ke W, Wang H, Zhao X, Lu Z. Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma. Food Funct 2021;12:1482-97. [PMID: 33502415 DOI: 10.1039/d0fo02243h] [Reference Citation Analysis]
9 Peng Y, He P, Gao X, Liu G, Cheng H. A Superstable Homogeneous Lipiodol-Nanoformulation to Overcome the Dilemma of Interventional Embolization Chemotherapy. Front Bioeng Biotechnol 2022;10:952194. [DOI: 10.3389/fbioe.2022.952194] [Reference Citation Analysis]
10 Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. J Viral Hepat 2021;28:538-47. [PMID: 33215790 DOI: 10.1111/jvh.13444] [Reference Citation Analysis]
11 Kabashima A, Shimada S, Shimokawa M, Akiyama Y, Tanabe M, Tanaka S. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. J Hepatobiliary Pancreat Sci 2021;28:62-75. [PMID: 33259135 DOI: 10.1002/jhbp.874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Yu MC, Ding GY, Ma P, Chen YD, Zhu XD, Cai JB, Shen YH, Zhou J, Fan J, Sun HC, Kuang M, Huang C. CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. Carcinogenesis 2021:bgab068. [PMID: 34314478 DOI: 10.1093/carcin/bgab068] [Reference Citation Analysis]
13 Zhang L. Single-Cell Profiling Explore the Immunologic Mechanisms of Tumor Relapse in Hepatocellular Carcinoma. Glob Med Genet 2021;8:83-4. [PMID: 34430957 DOI: 10.1055/s-0041-1729545] [Reference Citation Analysis]
14 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
15 Tang X, Liu B, Zhang C, Tang W, Liang S, Xiao Y, Deng R, Li Z. SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway. Front Oncol 2021;11:773045. [PMID: 34950583 DOI: 10.3389/fonc.2021.773045] [Reference Citation Analysis]
16 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 146] [Cited by in F6Publishing: 122] [Article Influence: 73.0] [Reference Citation Analysis]
17 Wang MH, Kuo YH, Yen YH, Lu SN, Wang JH, Chen CH, Hung CH, Kee KM. Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case. Case Rep Oncol 2021;14:906-11. [PMID: 34267637 DOI: 10.1159/000517024] [Reference Citation Analysis]
18 El Awady AA, Elshazli RM, El Awady AA, Elgaml A, Khalifa AK, Settin A. Association of CTLA4 c.49A > G (rs231775; p.Thr17Ala) gene variant with the risk of hepatocellular carcinoma and gastric cancer: A meta-analysis and meta-regression. Meta Gene 2022;31:100999. [DOI: 10.1016/j.mgene.2021.100999] [Reference Citation Analysis]
19 Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Fang W. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics 2021;11:3489-501. [PMID: 33537099 DOI: 10.7150/thno.54648] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
20 Su W, Wu L, Liang Q, Lin X, Xu X, Yu S, Lin Y, Zhou J, Fu Y, Gao X, Zhang B, Li L, Li D, Yin Y, Song G. Extraction Optimization, Structural Characterization, and Anti-Hepatoma Activity of Acidic Polysaccharides From Scutellaria barbata D. Don. Front Pharmacol 2022;13:827782. [PMID: 35444545 DOI: 10.3389/fphar.2022.827782] [Reference Citation Analysis]
21 Zhang X, Tao X, Feng F. Downregulation of C12orf75 gene inhibits migration and invasion of liver cancer cell via suppressing the Wnt/β-catenin signaling pathway in vitro. Biochemical and Biophysical Research Communications 2022;614:92-9. [DOI: 10.1016/j.bbrc.2022.05.018] [Reference Citation Analysis]
22 Chen W, Wang H, Li T, Liu T, Yang W, Jin A, Ding L, Zhang C, Pan B, Guo W, Wang B. A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion. BMC Med Genomics 2022;15:34. [PMID: 35197055 DOI: 10.1186/s12920-022-01162-7] [Reference Citation Analysis]
23 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 66.0] [Reference Citation Analysis]
25 Umemura T, Joshita S, Saito H, Wakabayashi SI, Kobayashi H, Yamashita Y, Sugiura A, Yamazaki T, Ota M. Investigation of the Effect of KIR-HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients. Cancers (Basel) 2021;13:3267. [PMID: 34209910 DOI: 10.3390/cancers13133267] [Reference Citation Analysis]
26 Marquardt P, Liu PH, Immergluck J, Olivares J, Arroyo A, Rich NE, Parikh ND, Yopp AC, Singal AG. Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. Hepatol Commun 2021;5:1481-9. [PMID: 34510836 DOI: 10.1002/hep4.1735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lin YH, Wu MH, Liu YC, Lyu PC, Yeh CT, Lin KH. LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing. Oncogene 2021;40:4675-85. [PMID: 34140643 DOI: 10.1038/s41388-021-01905-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Bai S, Hu L, Liu J, Sun M, Sun Y, Xue F. Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus–related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. Front Oncol 2022;12:919824. [DOI: 10.3389/fonc.2022.919824] [Reference Citation Analysis]
29 Maher S, Dowdell L, Zhang L, Zekry A. Community screening identifies undiagnosed chronic liver disease in high-risk populations. J Gastroenterol Hepatol 2021;36:2255-60. [PMID: 33638251 DOI: 10.1111/jgh.15473] [Reference Citation Analysis]
30 Escaliante LADS, Busato B, Petkowicz CLO, Cadena SMSC, Noleto GR. Cytotoxic effect of xyloglucan and oxovanadium (IV/V) xyloglucan complex in HepG2 cells. Int J Biol Macromol 2021;185:40-8. [PMID: 34144065 DOI: 10.1016/j.ijbiomac.2021.06.089] [Reference Citation Analysis]
31 Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00866-1. [PMID: 34391922 DOI: 10.1016/j.cgh.2021.08.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
33 Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2021;:1-8. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Reference Citation Analysis]
34 Tran NH. Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01160-5] [Reference Citation Analysis]
35 Liu M, Zhao Z, Cai Y, Bi P, Liang Q, Yan Y, Xu Z. YTH domain family: potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma. Aging (Albany NY) 2021;13:24205-18. [PMID: 34747720 DOI: 10.18632/aging.203674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
36 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Reference Citation Analysis]
37 Deng X, Bi Q, Chen S, Chen X, Li S, Zhong Z, Guo W, Li X, Deng Y, Yang Y. Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma. Front Mol Biosci 2020;7:611626. [PMID: 33505990 DOI: 10.3389/fmolb.2020.611626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Ramai D, Deliwala SS, Chandan S, Lester J, Singh J, Samanta J, di Nunzio S, Perversi F, Cappellini F, Shah A, Ghidini M, Sacco R, Facciorusso A, Giacomelli L. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers (Basel) 2022;14:2947. [PMID: 35740611 DOI: 10.3390/cancers14122947] [Reference Citation Analysis]
39 Su RY, Ling SB, Shan QN, Wei XY, Wang R, Jia CK, Zhuang L, Shen T, Ding LM, Xu ZD, Luo LB, Sun LB, Li GM, Fang TS, Jiang N, Zhang K, Su ZJ, Peng ZH, Lang R, Jiang T, He Q, Ye LS, Yang Y, He YT, Guo WZ, Lan LG, Sun XY, Chen D, Chen ZS, Zhou DW, Ye SJ, Ye QF, Tian M, Shi JH, Wang B, Liu J, Lu Q, Rao W, Cai JZ, Lv T, Yang JY, Wang PS, Zhong L, Ma JS, Li QG, Wu SD, Lu CJ, Lu CD, Zhang DH, Wang X, Li ZQ, Teng MJ, Li JJ, Jiang WT, Li JH, Zhang QB, Zhu NQ, Wang ZX, He K, Xia Q, Song SH, Fu ZR, Qiu W, Lv GY, Song RP, Wang JZ, Wang Z, Zhou J, Chen G, Zhao YP, Li L, Hu ZM, Luo QJ, Si ZZ, Xie B, He XS, Guo ZY, Zheng SS, Xu X. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00171-5. [PMID: 34583911 DOI: 10.1016/j.hbpd.2021.09.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
41 Zhao J, Gao S, Sun W, Grimm R, Fu C, Han J, Sheng R, Zeng M. Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma. Eur J Radiol 2021;139:109732. [PMID: 33905978 DOI: 10.1016/j.ejrad.2021.109732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Li L, Situ HJ, Ma WC, Liu X, Wang LL. Decreased DHRS1 expression is a novel predictor of poor survival in patients with hepatocellular carcinoma. Biomark Med 2021;15:1319-31. [PMID: 34498498 DOI: 10.2217/bmm-2021-0041] [Reference Citation Analysis]
43 Huang R, Chen Z, Li W, Fan C, Liu J. Immune system‑associated genes increase malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma. Int J Oncol 2020;56:1199-211. [PMID: 32319580 DOI: 10.3892/ijo.2020.4998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Su Z, Luo L, Wu X, Wei B, Wang L, Liu F, Cai B. Association of the MARCO polymorphism rs6761637 with hepatocellular carcinoma susceptibility and clinical characteristics. Immunol Res 2022. [PMID: 35364781 DOI: 10.1007/s12026-022-09271-2] [Reference Citation Analysis]
45 Mao D, Lau ESH, Wu H, Yang A, Fan B, Shi M, Tam CHT, Chow E, Kong APS, Ma RCW, Luk A, Chan JCN. Risk Associations of Glycemic Burden and Obesity With Liver Cancer-A 10-Year Analysis of 15,280 Patients With Type 2 Diabetes. Hepatol Commun 2022. [PMID: 35044101 DOI: 10.1002/hep4.1891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Xu XF, Liang L, Xing H, Shen F, Huang DS, Lau WY, Yang T. Clinical utility of serum biomarkers for hepatocellular carcinoma. Biomark Med 2021;15:151-5. [PMID: 33470867 DOI: 10.2217/bmm-2020-0474] [Reference Citation Analysis]
47 Salani F, Latarani M, Casadei-Gardini A, Gangadharannambiar P, Fornaro L, Vivaldi C, Pecora I, Massa V, Marisi G, Canale M, Ulivi P, Scartozzi M, Eccleston M, Masi G, Crea F. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics 2022. [PMID: 35473355 DOI: 10.2217/epi-2021-0383] [Reference Citation Analysis]
48 Chen Z, Ma Y, Guo Z, Song D, Chen Z, Sun M. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Guan MC, Ouyang W, Liu SY, Sun LY, Chen WY, Tong XM, Zhu H, Yang T. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00121-7. [PMID: 35643910 DOI: 10.1016/j.hbpd.2022.05.003] [Reference Citation Analysis]
50 Fu C, Lei H, Wang L, Wei C, Su C, Hou M, Huang Y, Lee P. Right inguinal metastasis from hepatocellular carcinoma. Adv in Digestive Med. [DOI: 10.1002/aid2.13277] [Reference Citation Analysis]
51 Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, Bonet L, Ryan P, Gea F, Díaz-Sánchez A, García-Mayor M, Martín-Carbonero L, Castillo P, Manzano ML, González-Moreno L, Pulido F, Gutiérrez ML, Moreno JM, García-Amengual IM, Cuevas G, Guerrero A, Rivero-Fernández M, Portales ME, Montes ML, Olveira A. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. Liver Int 2021;41:2885-91. [PMID: 34392590 DOI: 10.1111/liv.15032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Li H. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00375-3. [PMID: 34344577 DOI: 10.1016/j.dld.2021.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ram AK, Vairappan B, Srinivas BH. Nimbolide attenuates gut dysbiosis and prevents bacterial translocation by improving intestinal barrier integrity and ameliorating inflammation in hepatocellular carcinoma. Phytotherapy Research. [DOI: 10.1002/ptr.7434] [Reference Citation Analysis]
54 Lu H, Yin H, Qu L, Ma X, Fu R, Fan D. Ginsenoside Rk1 regulates glutamine metabolism in hepatocellular carcinoma through inhibition of the ERK/c-Myc pathway. Food Funct 2022;13:3793-811. [PMID: 35316310 DOI: 10.1039/d1fo03728e] [Reference Citation Analysis]
55 Liu C, Huang XY, Huang Y. FAM83G promotes proliferation, invasion, and metastasis by regulating PI3K/AKT signaling in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2021;567:63-71. [PMID: 34144502 DOI: 10.1016/j.bbrc.2021.05.081] [Reference Citation Analysis]
56 Suda T, Yamashita T, Sunagozaka H, Okada H, Nio K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma. Int J Mol Sci 2022;23:2801. [PMID: 35269944 DOI: 10.3390/ijms23052801] [Reference Citation Analysis]
57 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
58 Liu Z, Shi O, Zhang T, Jin L, Chen X. Disease burden of viral hepatitis A, B, C and E: A systematic analysis. J Viral Hepat 2020;27:1284-96. [PMID: 32741034 DOI: 10.1111/jvh.13371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Ayoub WS, Jones PD, Yang JD, Martin P. Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2022. [PMID: 35642526 DOI: 10.1080/14728214.2022.2083107] [Reference Citation Analysis]
60 Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS, Nath LR. Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. J Food Biochem 2021;45:e13761. [PMID: 34028054 DOI: 10.1111/jfbc.13761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
61 Xu Y, Jiang J, Wang H, Yu W, Sun G. Synthesis and Preclinical Evaluation of [68Ga]SP94 for Micro-PET Imaging of GRP78 Expression in Hepatocellular Carcinoma. ACS Med Chem Lett 2021;12:1553-8. [PMID: 34676037 DOI: 10.1021/acsmedchemlett.1c00350] [Reference Citation Analysis]
62 Yu B, Liang H, Ye Q, Wang Y. Upregulation of ERCC6L is associated with tumor progression and unfavorable prognosis in hepatocellular carcinoma. J Gastrointest Oncol 2020;11:1009-23. [PMID: 33209494 DOI: 10.21037/jgo-20-192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Lu Q, Guo Q, Xin M, Lim C, Gamero AM, Gerhard GS, Yang L. LncRNA TP53TG1 Promotes the Growth and Migration of Hepatocellular Carcinoma Cells via Activation of ERK Signaling. Noncoding RNA 2021;7:52. [PMID: 34564314 DOI: 10.3390/ncrna7030052] [Reference Citation Analysis]
64 Wu MN, Zheng WJ, Ye WX, Wang L, Chen Y, Yang J, Yao DF, Yao M. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth. World J Gastroenterol 2021; 27(23): 3327-3341 [PMID: 34163115 DOI: 10.3748/wjg.v27.i23.3327] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Chen S, Zhang Y, Ding X, Li W. Identification of lncRNA/circRNA-miRNA-mRNA ceRNA Network as Biomarkers for Hepatocellular Carcinoma. Front Genet 2022;13:838869. [PMID: 35386284 DOI: 10.3389/fgene.2022.838869] [Reference Citation Analysis]
66 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
67 Zhu F, Wang BR, Zhu ZF, Wang SQ, Chai CX, Shang D, Li M. Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma? World J Gastrointest Surg 2021; 13(12): 1523-1535 [DOI: 10.4240/wjgs.v13.i12.1523] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Dai T, Li J, Lu X, Ye L, Yu H, Zhang L, Deng M, Zhu S, Liu W, Wang G, Yang Y. Prognostic Role and Potential Mechanisms of the Ferroptosis-Related Metabolic Gene Signature in Hepatocellular Carcinoma. Pharmgenomics Pers Med 2021;14:927-45. [PMID: 34377010 DOI: 10.2147/PGPM.S319524] [Reference Citation Analysis]
69 Kang SM, Khalil L, El-Rayes BF, Akce M. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Front Oncol 2022;12:821903. [PMID: 35433430 DOI: 10.3389/fonc.2022.821903] [Reference Citation Analysis]
70 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
71 Feng LH, Sun HC, Zhu XD, Zhang SZ, Li XL, Li KS, Liu XF, Lei M, Li Y, Tang ZY. Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma. Ann Transl Med 2021;9:207. [PMID: 33708834 DOI: 10.21037/atm-20-5293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Chen CT, Liu TH, Shao YY, Liu KL, Liang PC, Lin ZZ. Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. Int J Mol Sci 2021;22:12880. [PMID: 34884684 DOI: 10.3390/ijms222312880] [Reference Citation Analysis]
73 Li AM, Lin XW, Shen JT, Li M, Zheng QH, Zhou ZY, Shi M. HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging. Nucl Med Biol 2021;96-97:27-34. [PMID: 33725499 DOI: 10.1016/j.nucmedbio.2021.02.006] [Reference Citation Analysis]
74 Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci Rep 2022;12:1517. [PMID: 35087153 DOI: 10.1038/s41598-022-05444-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Zhou ZY, Liu SR, Xu LB, Liu C, Zhang R. Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis. J Clin Transl Hepatol 2021;9:889-97. [PMID: 34966652 DOI: 10.14218/JCTH.2021.00056] [Reference Citation Analysis]
76 Wang JY, Wang XK, Zhu GZ, Zhou X, Yao J, Ma XP, Wang B, Peng T. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer 2021;21:462. [PMID: 33902495 DOI: 10.1186/s12885-021-08104-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Parisse S, Ferri F, Persichetti M, Mischitelli M, Abbatecola A, Di Martino M, Lai Q, Carnevale S, Lucatelli P, Bezzi M, Rossi M, De Santis A, Spagnoli A, Ginanni Corradini S. Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients. Sci Rep 2021;11:15184. [PMID: 34312420 DOI: 10.1038/s41598-021-94509-6] [Reference Citation Analysis]
78 Sun X, Hu D, Yang Z, Liu Z, Wang J, Chen J, Xu L, Zhou Z, Chen M, Zhang Y. Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy. J Hepatocell Carcinoma 2020;7:337-45. [PMID: 33294424 DOI: 10.2147/JHC.S278527] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Zhao Y, Wu L, Qin H, Li Q, Shen C, He Y, Yang H. Preoperative combi-elastography for the prediction of early recurrence after curative resection of hepatocellular carcinoma. Clin Imaging 2021;79:173-8. [PMID: 34087717 DOI: 10.1016/j.clinimag.2021.05.020] [Reference Citation Analysis]
80 Kim NJ, Jacob DA, Ioannou GN, John BV, Rogal S, Rozenberg-Ben-Dror K. Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. Am J Gastroenterol 2021;116:411-5. [PMID: 33252455 DOI: 10.14309/ajg.0000000000001000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
81 Peraldo-Neia C, Massa A, Vita F, Basiricò M, Raggi C, Bernabei P, Ostano P, Casorzo L, Panero M, Leone F, Cavalloni G, Aglietta M. A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. Cancers (Basel) 2021;13:2051. [PMID: 33922695 DOI: 10.3390/cancers13092051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Greca RD, Cunha-silva M, Mazo DF, Costa LB, Ataíde EC, Boin IF, Sevá-pereira T. Prevalence of Hepatocellular Carcinoma and Its Characteristics in 10 Years of Transplantation in a University Hospital in Brazil. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.03.010] [Reference Citation Analysis]
83 Gumilas NSA, Widodo I, Ratnasari N, Heriyanto DS. Potential relative quantities of miR-122 and miR-150 to differentiate hepatocellular carcinoma from liver cirrhosis. Non-coding RNA Research 2022;7:34-9. [DOI: 10.1016/j.ncrna.2022.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Trejo-Solis C, Escamilla-Ramirez A, Jimenez-Farfan D, Castillo-Rodriguez RA, Flores-Najera A, Cruz-Salgado A. Crosstalk of the Wnt/β-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells. Pharmaceuticals (Basel) 2021;14:871. [PMID: 34577571 DOI: 10.3390/ph14090871] [Reference Citation Analysis]
86 Yu H, Wang C, Ke S, Bai M, Xu Y, Lu S, Feng Z, Qian B, Xu Y, Zhou M, Li Z, Yin B, Li X, Hua Y, Zhou Y, Pan S, Fu Y, Ma Y. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma. Front Immunol 2022;13:892750. [DOI: 10.3389/fimmu.2022.892750] [Reference Citation Analysis]
87 Li Y, Li Y, Zhang J, Ji L, Li M, Sun X, Feng H, Yu Z, Gao Y. Current Perspective of Traditional Chinese Medicines and Active Ingredients in the Therapy of Hepatocellular Carcinoma. JHC 2022;Volume 9:41-56. [DOI: 10.2147/jhc.s346047] [Reference Citation Analysis]
88 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
89 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
90 Zhou Z, Wang T, Du Y, Deng J, Gao G, Zhang J. Identification of a Novel Glycosyltransferase Prognostic Signature in Hepatocellular Carcinoma Based on LASSO Algorithm. Front Genet 2022;13:823728. [PMID: 35356430 DOI: 10.3389/fgene.2022.823728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Shigesawa T, Maehara O, Suda G, Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. Carcinogenesis 2021;42:58-69. [PMID: 32449510 DOI: 10.1093/carcin/bgaa049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
92 Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D, Chow PKH. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers (Basel) 2021;13:2626. [PMID: 34071818 DOI: 10.3390/cancers13112626] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Li T, Zhang X, Lv Z, Gao L, Yan H. Increased Expression of Myeloid-Derived Suppressor Cells in Patients with HBV-Related Hepatocellular Carcinoma. Biomed Res Int 2020;2020:6527192. [PMID: 32258134 DOI: 10.1155/2020/6527192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Liu Y, Hu C, Qu X, Chen H, Liu L, Zhou L, Liu S, Li G, Zhou Y. Novel Role of Long Non-Coding RNA ASAP1-IT1 in Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:746896. [DOI: 10.3389/fonc.2022.746896] [Reference Citation Analysis]
95 Li X, Yu Y, Liu L. Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis. Clin Res Hepatol Gastroenterol 2020;:101545. [PMID: 33067170 DOI: 10.1016/j.clinre.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Martínez-Iglesias O, Carrera I, Naidoo V, Cacabelos R. AntiGan: An Epinutraceutical Bioproduct with Antitumor Properties in Cultured Cell Lines. Life (Basel) 2022;12:97. [PMID: 35054489 DOI: 10.3390/life12010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Feng Y, Dramani Maman ST, Zhu X, Liu X, Bongolo CC, Liang C, Tu J. Clinical value and potential mechanisms of LINC00221 in hepatocellular carcinoma based on integrated analysis. Epigenomics 2021;13:299-317. [PMID: 33406920 DOI: 10.2217/epi-2020-0363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Hagiwara H, Ito Y, Ohta T, Nozaki Y, Iwamoto T, Hosui A, Hiramatsu N, Tahata Y, Sakamori R, Hikita H, Hayashi N. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct‐acting antiviral agents among the working population in Japan. JGH Open. [DOI: 10.1002/jgh3.12745] [Reference Citation Analysis]
99 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 42] [Article Influence: 46.0] [Reference Citation Analysis]
100 Liu ZK, Wu KF, Zhang RY, Kong LM, Shang RZ, Lv JJ, Li C, Lu M, Yong YL, Zhang C, Zheng NS, Li YH, Chen ZN, Bian H, Wei D. Pyroptosis-Related LncRNA Signature Predicts Prognosis and Is Associated With Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2022;12:794034. [PMID: 35311105 DOI: 10.3389/fonc.2022.794034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Castellana M, Donghia R, Lampignano L, Castellana F, Zupo R, Sardone R, Pergola G, Giannelli G. Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:4638. [PMID: 34682759 DOI: 10.3390/jcm10204638] [Reference Citation Analysis]
102 Zhong W, Liu H, Deng L, Chen G, Liu Y. HBO1 overexpression is important for hepatocellular carcinoma cell growth. Cell Death Dis 2021;12:549. [PMID: 34039960 DOI: 10.1038/s41419-021-03818-1] [Reference Citation Analysis]
103 Ram AK, Vairappan B, Srinivas BH. Nimbolide inhibits tumor growth by restoring hepatic tight junction protein expression and reduced inflammation in an experimental hepatocarcinogenesis. World J Gastroenterol 2020; 26(45): 7131-7152 [PMID: 33362373 DOI: 10.3748/wjg.v26.i45.7131] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
104 Zhang C, Feng S, Tu Z, Sun J, Rui T, Zhang X, Huang H, Ling Q, Zheng S. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. Cancer Med 2021. [PMID: 34331411 DOI: 10.1002/cam4.4162] [Reference Citation Analysis]
105 Huang Y, Yang X, Meng Y, Shao C, Liao J, Li F, Li R, Jing Y, Huang A. The hepatic senescence-associated secretory phenotype promotes hepatocarcinogenesis through Bcl3-dependent activation of macrophages. Cell Biosci 2021;11:173. [PMID: 34530917 DOI: 10.1186/s13578-021-00683-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35859026 DOI: 10.1038/s41575-022-00649-z] [Reference Citation Analysis]
107 Zhang S, Zhao H, Chen Y, Zhang Y, Zhong WL. GNL3 Regulates SIRT1 Transcription and Promotes Hepatocellular Carcinoma Stem Cell-Like Features and Metastasis. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/1555670] [Reference Citation Analysis]
108 Wu A, Li Y, Kong M, Zhu B, Liu R, Bao F, Ju S, Chen L, Wang F. Upregulated hsa_circ_0005785 Facilitates Cell Growth and Metastasis of Hepatocellular Carcinoma Through the miR-578/APRIL Axis. Front Oncol 2020;10:1388. [PMID: 32974140 DOI: 10.3389/fonc.2020.01388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
109 Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
110 Chang CY, Wei CY, Chen PH, Hou MC, Chao Y, Chau GY, Lee RC, Huang YH, Su YH, Wu JC, Su CW. The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. J Chin Med Assoc 2021;84:136-43. [PMID: 33433133 DOI: 10.1097/JCMA.0000000000000482] [Reference Citation Analysis]
111 Chen Y, Wang W. Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis. Clin Hemorheol Microcirc 2021. [PMID: 33935070 DOI: 10.3233/CH-211145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Icard P, Simula L, Wu Z, Berzan D, Sogni P, Dohan A, Dautry R, Coquerel A, Lincet H, Loi M, Fuks D. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? Drug Resist Updat 2021;:100790. [PMID: 34924279 DOI: 10.1016/j.drup.2021.100790] [Reference Citation Analysis]
114 Lee C, Chan SL, Chon HJ. Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma? Cancers 2022;14:3213. [DOI: 10.3390/cancers14133213] [Reference Citation Analysis]
115 Jepsen P, West J. We need stronger evidence for (or against) hepatocellular carcinoma surveillance. J Hepatol 2021;74:1234-9. [PMID: 33465402 DOI: 10.1016/j.jhep.2020.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
116 Li Y, Xu C, Sun B, Zhong F, Cao M, Yang L. Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA. Front Oncol 2022;12:913498. [DOI: 10.3389/fonc.2022.913498] [Reference Citation Analysis]
117 Shi J, Guo C, Ma J. CCAT2 enhances autophagy-related invasion and metastasis via regulating miR-4496 and ELAVL1 in hepatocellular carcinoma. J Cell Mol Med 2021;25:8985-96. [PMID: 34409736 DOI: 10.1111/jcmm.16859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Tang S, Zhang X, Ma Y, Huang X, Geng C, Li T, Zhang X, Shen C, Su L, Gao Z, Chen J. Artemyrianolides A–S, Cytotoxic Sesquiterpenoids from Artemisia myriantha. J Nat Prod 2020;83:2618-30. [DOI: 10.1021/acs.jnatprod.0c00396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
119 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
120 Zheng Q, Yang Q, Zhou J, Gu X, Zhou H, Dong X, Zhu H, Chen Z. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions. Cancer Cell Int 2021;21:330. [PMID: 34193146 DOI: 10.1186/s12935-021-02033-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Anugwom CM, Kayandabila J, Flanagan S, Debes JD. A Case of Infiltrative Hepatocellular Carcinoma With Vascular Invasion Into the Heart. Cureus 2021;13:e17859. [PMID: 34660063 DOI: 10.7759/cureus.17859] [Reference Citation Analysis]
122 Micali C, Russotto Y, Caci G, Ceccarelli M, Marino A, Celesia BM, Pellicanò GF, Nunnari G, Venanzi Rullo E. Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV. Infectious Disease Reports 2022;14:43-55. [DOI: 10.3390/idr14010006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
123 Zhang L, Hu J, Hou J, Jiang X, Guo L, Tian L. Radiomics-based model using gadoxetic acid disodium-enhanced MR images: associations with recurrence-free survival of patients with hepatocellular carcinoma treated by surgical resection. Abdom Radiol (NY) 2021;46:3845-54. [PMID: 33733337 DOI: 10.1007/s00261-021-03034-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
124 Ibrahim HM, Elghannam MZ, Elkhawaga OAY, El-sokkary AM. Evaluation of serum alpha fetoprotein-L3 as an accuracy novel biomarker for the early diagnosis of hepatocellular carcinoma in Egyptian patients. Saudi Journal of Biological Sciences 2021. [DOI: 10.1016/j.sjbs.2021.06.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
127 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
128 Takaki K, Nakano M, Fukumori K, Yano Y, Zaizen Y, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Torimura T. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. J Clin Med 2022;11:1483. [PMID: 35329809 DOI: 10.3390/jcm11061483] [Reference Citation Analysis]
129 Han LY, Yang JR, Zhao ZH, Gao S, Fan YC, Wang K. RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2020;216:153147. [PMID: 32853963 DOI: 10.1016/j.prp.2020.153147] [Reference Citation Analysis]
130 Li J, Liu ZY, Yu HB, Xue Q, Qu XS. Effects of oxymatrine on the proliferation of human liver cancer Bel-7404 cells: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20181. [PMID: 32501970 DOI: 10.1097/MD.0000000000020181] [Reference Citation Analysis]
131 Dakurah OB, Tamandjou CRT, Zunza M, Preiser W, Maponga TG. Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review. BMC Cancer 2021;21:715. [PMID: 34144696 DOI: 10.1186/s12885-021-08426-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Han S, Kim DY. Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma. Clin Mol Hepatol 2020;26:305-8. [PMID: 32646205 DOI: 10.3350/cmh.2020.0096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Abd El-Fattah EE, Saber S, Youssef ME, Eissa H, El-Ahwany E, Amin NA, Alqarni M, Batiha GE, Obaidullah AJ, Kaddah MMY, Ahmed Gaafar AG, Mourad AAE, Mostafa-Hedeab G, Abdelhamid AM. AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma. Front Pharmacol 2021;12:720173. [PMID: 35095479 DOI: 10.3389/fphar.2021.720173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
134 Haberl EM, Pohl R, Rein-Fischboeck L, Höring M, Krautbauer S, Liebisch G, Buechler C. Accumulation of cholesterol, triglycerides and ceramides in hepatocellular carcinomas of diethylnitrosamine injected mice. Lipids Health Dis 2021;20:135. [PMID: 34629057 DOI: 10.1186/s12944-021-01567-w] [Reference Citation Analysis]
135 Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
136 Ouyang X, Lv L, Zhao Y, Zhang F, Hu Q, Li Z, Zhu D, Li L. ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma. Front Oncol 2021;11:801506. [PMID: 35087760 DOI: 10.3389/fonc.2021.801506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
137 Hong X, Luo H, Zhu G, Guan X, Jia Y, Yu H, Lv X, Yu T, Lan H, Zhang Q, Li H, Sun W, Huang X, Li J. SSR2 overexpression associates with tumorigenesis and metastasis of Hepatocellular Carcinoma through modulating EMT. J Cancer 2020;11:5578-87. [PMID: 32913453 DOI: 10.7150/jca.44788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
139 Chong N, Schoenberger H, Yekkaluri S, Fetzer DT, Rich NE, Yokoo T, Gopal P, Manwaring C, Quirk L, Singal AG. Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment Pharmacol Ther 2022. [PMID: 35170052 DOI: 10.1111/apt.16779] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
140 Ikeda M, Okusaka T, Ohno I, Mitsunaga S, Kondo S, Ueno H, Morizane C, Gemmoto K, Suna H, Ushida Y, Furuse J. Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy 2021;13:371-85. [PMID: 33525928 DOI: 10.2217/imt-2020-0278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Zhang J, Ma X, Fan D. Ginsenoside CK Inhibits Hypoxia-Induced Epithelial-Mesenchymal Transformation through the HIF-1α/NF-κB Feedback Pathway in Hepatocellular Carcinoma. Foods 2021;10:1195. [PMID: 34073155 DOI: 10.3390/foods10061195] [Reference Citation Analysis]
142 Berning P, Maybody M, Deipolyi AR, Solomon SB, Dzaye O. Internet Search Trends Relevant to Interventional Oncology: A Google Trends Study (2004-2020). J Vasc Interv Radiol 2021;32:1445-1448.e1. [PMID: 34602160 DOI: 10.1016/j.jvir.2021.07.005] [Reference Citation Analysis]
143 Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang X, Zeng W, Ma L, Xie J. Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Mol Ther Nucleic Acids 2020;22:937-47. [PMID: 33251044 DOI: 10.1016/j.omtn.2020.10.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
144 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Nahon P, Allaire M, Nault JC, Paradis V. Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepat Oncol 2020;7:HEP36. [PMID: 33680428 DOI: 10.2217/hep-2020-0017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
146 Wu SY, Yang WY, Cheng CC, Lin KH, Sampurna BP, Chan SM, Yuh CH. Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling. Clin Transl Med 2020;10:e252. [PMID: 33377648 DOI: 10.1002/ctm2.252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
147 Chen H, Tao M, Li D, Han J, Cheng C, Ma Y, Wu Y, Shelat VG, Tustumi F, Satapathy SK, Kang KJ, Wang Q. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. Ann Transl Med 2021;9:1004. [PMID: 34277804 DOI: 10.21037/atm-21-2611] [Reference Citation Analysis]
148 Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229 [DOI: 10.3748/wjg.v28.i2.216] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
149 Saraswat A, Vemana HP, Dukhande VV, Patel K. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon 2022;8:e08702. [PMID: 35036599 DOI: 10.1016/j.heliyon.2021.e08702] [Reference Citation Analysis]
150 Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022;75:541-9. [PMID: 34618932 DOI: 10.1002/hep.32185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
151 Feng LH, Sun HC, Zhu XD, Liu XF, Zhang SZ, Li XL, Li Y, Tang ZY. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur J Surg Oncol 2021;47:681-9. [PMID: 33189491 DOI: 10.1016/j.ejso.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Masch WR, Kampalath R, Parikh N, Shampain KA, Aslam A, Chernyak V. Imaging of treatment response during systemic therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3625-33. [PMID: 33950406 DOI: 10.1007/s00261-021-03100-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Ayares G, Idalsoaga F, Díaz LA, Arnold J, Arab JP. Current Medical Treatment for Alcohol-Associated Liver Disease. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.02.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Farinha D, Migawa M, Sarmento-Ribeiro A, Faneca H. A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma. Int J Nanomedicine 2021;16:3385-405. [PMID: 34040370 DOI: 10.2147/IJN.S302288] [Reference Citation Analysis]
155 Van Hees S, Muyindike W, Erem G, Ocama P, Seremba E, Paska A, Michielsen P, Okwir M, Vanwolleghem T. Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda. Journal of Hepatology 2020;73:1271-3. [DOI: 10.1016/j.jhep.2020.05.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Saeed RA, Maqsood M, Saeed RA, Muzammil HS, Khan MI, Asghar L, Nisa SU, Rabail R, Aadil RM. Plant-based foods and hepatocellular carcinoma: A review on mechanistic understanding. Crit Rev Food Sci Nutr 2022;:1-34. [PMID: 35796706 DOI: 10.1080/10408398.2022.2095974] [Reference Citation Analysis]
157 Wang X, Liu X, Wang P, Yu L, Yan F, Yan H, Zhou D, Yang Z. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia. J Hepatocell Carcinoma 2021;8:1253-67. [PMID: 34708007 DOI: 10.2147/JHC.S330301] [Reference Citation Analysis]
158 Zhang L, Ke W, Zhao X, Lu Z. Resina Draconis extract exerts anti-HCC effects through METTL3-m6A-Survivin axis. Phytother Res 2022. [PMID: 35443090 DOI: 10.1002/ptr.7467] [Reference Citation Analysis]
159 Ma L, Wang XW. Dissecting liver tumor heterogeneity to improve health equity. Trends Cancer 2022:S2405-8033(21)00249-1. [PMID: 35012904 DOI: 10.1016/j.trecan.2021.12.001] [Reference Citation Analysis]
160 Lewis S, Cedillo MA, Lee KM, Bane O, Hectors S, Ma W, Wang P, Stocker D, Morris DV, Pinato D, Sung M, Marron T, Schwartz M, Taouli B. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdom Radiol (NY) 2022;47:969-80. [PMID: 34964909 DOI: 10.1007/s00261-021-03386-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Chen TY, Mai JY, Zhang P, Xue JH, He SL, Xi J, Chen JJ, Cheng Y. Efficacy of erzhu jiedu recipe on hepatitis B cirrhosis with hyperalphafetoproteinemia: A randomized, double-blind, placebo-controlled clinical trial. Medicine (Baltimore) 2021;100:e27231. [PMID: 34559118 DOI: 10.1097/MD.0000000000027231] [Reference Citation Analysis]
162 Wong VC, Wong MI, Lam CT, Lung ML, Lam KO, Lee VH. Hallmark microRNA signature in liquid biopsy identifies hepatocellular carcinoma and differentiates it from liver metastasis. J Cancer 2021;12:4585-94. [PMID: 34149922 DOI: 10.7150/jca.59933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
163 Lockart I, Hajarizadeh B, Buckley N, Davison S, Prakoso E, Levy MT, George J, Dore GJ, Danta M. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol 2021. [PMID: 34520088 DOI: 10.1111/jgh.15687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Guijarro LG, Sanmartin-Salinas P, Pérez-Cuevas E, Toledo-Lobo MV, Monserrat J, Zoullas S, Sáez MA, Álvarez-Mon MA, Bujan J, Noguerales-Fraguas F, Arilla-Ferreiro E, Álvarez-Mon M, Ortega MA. Possible Role of IRS-4 in the Origin of Multifocal Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2560. [PMID: 34071030 DOI: 10.3390/cancers13112560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
165 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med 2022. [PMID: 35441477 DOI: 10.1002/cam4.4763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
166 Sosnowska M, Kutwin M, Strojny B, Wierzbicki M, Cysewski D, Szczepaniak J, Ficek M, Koczoń P, Jaworski S, Chwalibog A, Sawosz E. Diamond Nanofilm Normalizes Proliferation and Metabolism in Liver Cancer Cells. Nanotechnol Sci Appl 2021;14:115-37. [PMID: 34511890 DOI: 10.2147/NSA.S322766] [Reference Citation Analysis]
167 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
168 Lin C, Kuo JC, Li D, Koenig AB, Pan A, Yan P, Bai X, Lee RJ, Ghoshal K. AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells. Front Cell Dev Biol 2022;10:853652. [DOI: 10.3389/fcell.2022.853652] [Reference Citation Analysis]
169 Li G, Chen W, Mi D, Wang B, Li H, Wu G, Ding P, Liang J, Zhou Z. A highly sensitive strategy for glypican-3 detection based on aptamer/gold carbon dots/magnetic graphene oxide nanosheets as fluorescent biosensor. Anal Bioanal Chem 2022. [PMID: 35788872 DOI: 10.1007/s00216-022-04201-5] [Reference Citation Analysis]
170 Zhu J, Han T, Zhao S, Zhu Y, Ma S, Xu F, Bai T, Tang Y, Xu Y, Liu L. Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. Front Oncol 2022;12:933210. [DOI: 10.3389/fonc.2022.933210] [Reference Citation Analysis]
171 Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol 2020;27:S138-43. [PMID: 33343207 DOI: 10.3747/co.27.7181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
172 Liu X, Liu F, Yu H, Zhang Q, Liu F. Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma. IJGM 2022;Volume 15:3625-37. [DOI: 10.2147/ijgm.s351265] [Reference Citation Analysis]
173 Wang J, Lou J, Fu L, Jin Q. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment. J Int Med Res 2021;49:300060520980646. [PMID: 33567957 DOI: 10.1177/0300060520980646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Zhang Z, Yang G, Fan F, Zhong C, Yuan Y, Zhang X, Chang S. Terahertz circular dichroism sensing of living cancer cells based on microstructure sensor. Anal Chim Acta 2021;1180:338871. [PMID: 34538326 DOI: 10.1016/j.aca.2021.338871] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Baj J, Bryliński Ł, Woliński F, Granat M, Kostelecka K, Duda P, Flieger J, Teresiński G, Buszewicz G, Furtak-Niczyporuk M, Portincasa P. Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know. Cancers (Basel) 2022;14:1493. [PMID: 35326644 DOI: 10.3390/cancers14061493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Zhang H, Liu R, Sun L, Hu X. A Reliable Prognostic Model for HCC Using Histological Grades and the Expression Levels of Related Genes. J Oncol 2021;2021:9512774. [PMID: 34659413 DOI: 10.1155/2021/9512774] [Reference Citation Analysis]
177 Nahon P, Ronot M. Repeating Ultrasound for Hepatocellular Carcinoma Detection in Case of Inadequate Liver Visualization: A Matter of Expertise. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00826-0. [PMID: 34358716 DOI: 10.1016/j.cgh.2021.07.044] [Reference Citation Analysis]
178 Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F;  ITA. LI.CA study group. The changing scenario of hepatocellular carcinoma in Italy: an update.Liver Int. 2021;41:585-597. [PMID: 33219585 DOI: 10.1111/liv.14735] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
179 Javan H, Dayyani F, Abi-Jaoudeh N. Therapy in Advanced Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:466-74. [PMID: 33328702 DOI: 10.1055/s-0040-1719187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
180 Kwon JH, Lee JW, Lee JW, Lee YJ. Effects of Anatomical or Non-Anatomical Resection of Hepatocellular Carcinoma on Survival Outcome. J Clin Med 2022;11:1369. [PMID: 35268459 DOI: 10.3390/jcm11051369] [Reference Citation Analysis]
181 Dehghani-dehej F, Hosseini Z, Mortazkar P, Khanaliha K, Esghaei M, Fakhim A, Bokharaei-salim F. Prevalence of HCV and/or HBV coinfection in Iranian HIV-infected patients. Future Virology 2020;15:155-63. [DOI: 10.2217/fvl-2019-0066] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
182 Thangavelu L, Geetha RV, Devaraj E, Dua K, Chellappan DK, Balusamy SR. Acacia catechu seed extract provokes cytotoxicity via apoptosis by intrinsic pathway in HepG2 cells. Environ Toxicol 2021. [PMID: 34800081 DOI: 10.1002/tox.23411] [Reference Citation Analysis]
183 Chang H, Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis. Clin Exp Med 2022. [PMID: 35737170 DOI: 10.1007/s10238-022-00842-z] [Reference Citation Analysis]
184 Unfried JP, Sangro P, Prats-Mari L, Sangro B, Fortes P. The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers (Basel) 2021;13:2651. [PMID: 34071216 DOI: 10.3390/cancers13112651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 2020;72:209-14. [PMID: 31954486 DOI: 10.1016/j.jhep.2019.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
186 Mancuso A, Pourfathi M, Kiefer RM, Noji MC, Siddiqui S, Profka E, Weber CN, Pantel A, Kadlecek SJ, Rizi R, Gade TPF. Radial Flow Perfusion Enables Real-Time Profiling of Cellular Metabolism at Low Oxygen Levels with Hyperpolarized 13C NMR Spectroscopy. Metabolites 2021;11:576. [PMID: 34564392 DOI: 10.3390/metabo11090576] [Reference Citation Analysis]
187 Yin X, Yu H, He XK, Yan SX. Prognostic and biological role of the N-Myc downstream-regulated gene family in hepatocellular carcinoma. World J Clin Cases 2022; 10(7): 2072-2086 [DOI: 10.12998/wjcc.v10.i7.2072] [Reference Citation Analysis]
188 Cai Q, Gan C, Tang C, Wu H, Gao J. Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front Pharmacol 2021;12:784591. [PMID: 34887768 DOI: 10.3389/fphar.2021.784591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
189 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
190 Juaid N, Amin A, Abdalla A, Reese K, Alamri Z, Moulay M, Abdu S, Miled N. Anti-Hepatocellular Carcinoma Biomolecules: Molecular Targets Insights. Int J Mol Sci 2021;22:10774. [PMID: 34639131 DOI: 10.3390/ijms221910774] [Reference Citation Analysis]
191 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
192 Vardar BU, Meram E, Karaoglu K, Liang M, Yu M, Laeseke P, Ozkan OS. Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma. Cureus. [DOI: 10.7759/cureus.23783] [Reference Citation Analysis]
193 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
194 Wang W, Ye Y, Zhang X, Ye X, Liu C, Bao L. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:937979. [DOI: 10.3389/fmolb.2022.937979] [Reference Citation Analysis]
195 Bai S, Yang P, Xie Z, Li J, Lei Z, Xia Y, Qian G, Zhang B, Pawlik TM, Lau WY, Shen F. Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2021;28:8174-85. [PMID: 34409542 DOI: 10.1245/s10434-021-09901-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Fontanellas A, Avila MA. Hydroxymethylbilane synthase (aka porphobilinogen deaminase): a novel metabolic tumor suppressor gene in hepatocellular carcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.06.023] [Reference Citation Analysis]
197 Nahon P, Najean M, Layese R, Zarca K, Segar LB, Cagnot C, Ganne-Carrié N, N'Kontchou G, Pol S, Chaffaut C, Carrat F, Ronot M, Audureau E, Durand-Zaleski I; ANRS CO12 CirVir., ANRS CO22 Hepather., Scientific Committee – Voting members., CIRRAL groups. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Rep 2022;4:100390. [PMID: 34977518 DOI: 10.1016/j.jhepr.2021.100390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 van Dijk M, Drenth JPH; HepNed study group. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination. J Viral Hepat 2020;27:1270-83. [PMID: 32964615 DOI: 10.1111/jvh.13399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Sudhindar PD, Wainwright D, Saha S, Howarth R, McCain M, Bury Y, Saha SS, McPherson S, Reeves H, Patel AH, Faulkner GJ, Lunec J, Shukla R. HCV Activates Somatic L1 Retrotransposition-A Potential Hepatocarcinogenesis Pathway. Cancers (Basel) 2021;13:5079. [PMID: 34680227 DOI: 10.3390/cancers13205079] [Reference Citation Analysis]
200 Xi B, Luo F, He B, Wang F, Li Z, Lai M, Zheng S. High nuclear ABCG1 expression is a poor predictor for hepatocellular carcinoma patient survival. Hepatobiliary & Pancreatic Diseases International 2022. [DOI: 10.1016/j.hbpd.2022.06.009] [Reference Citation Analysis]
201 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
202 Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nguyen MH. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. Hepatol Commun 2021;5:122-32. [PMID: 33437906 DOI: 10.1002/hep4.1606] [Reference Citation Analysis]
203 Shi T, Morishita A, Kobara H, Masaki T. The Role of Long Non-Coding RNA and microRNA Networks in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci 2021;22:10630. [PMID: 34638971 DOI: 10.3390/ijms221910630] [Reference Citation Analysis]
204 Yang ZC, Luo MJ, Liu LL, Cai MY, Liang YJ, Chen QY, Tang LQ, Mai HQ. Alpha-fetoprotein-producing recurrent nasopharyngeal carcinoma: A case report. SAGE Open Med Case Rep 2021;9:2050313X211057704. [PMID: 34777811 DOI: 10.1177/2050313X211057704] [Reference Citation Analysis]
205 Liang Y, Chang C, Sheu M, Lin S, Chung C, Teng C, Suk F. The Antihistamine Deptropine Induces Hepatoma Cell Death through Blocking Autophagosome-Lysosome Fusion. Cancers 2020;12:1610. [DOI: 10.3390/cancers12061610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
206 Giannis D, Morsy S, Geropoulos G, Esagian SM, Sioutas GS, Moris D. The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. In Vivo 2021;35:393-9. [PMID: 33402488 DOI: 10.21873/invivo.12270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
207 Deng H, Shang W, Wang K, Guo K, Liu Y, Tian J, Fang C. Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles. J Nanobiotechnology 2022;20:156. [PMID: 35331259 DOI: 10.1186/s12951-022-01378-w] [Reference Citation Analysis]
208 Lambrecht J, Porsch-Özçürümez M, Best J, Jost-Brinkmann F, Roderburg C, Demir M, Tacke F, Mohr R. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. J Clin Med 2021;10:3392. [PMID: 34362181 DOI: 10.3390/jcm10153392] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Fang Q, Liu H, Zhou A, Zhou H, Zhang Z. Circ_0046599 Promotes the Development of Hepatocellular Carcinoma by Regulating the miR-1258/RPN2 Network. Cancer Manag Res 2020;12:6849-60. [PMID: 32801909 DOI: 10.2147/CMAR.S253510] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
210 Khan S, Zhang D, Zhang J, Hayat MK, Ren J, Nasir S, Fawad M, Bai Q. The Key Role of microRNAs in Initiation and Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:950374. [DOI: 10.3389/fonc.2022.950374] [Reference Citation Analysis]
211 Zhang C, Li L, Hou S, Shi Z, Xu W, Wang Q, He Y, Gong Y, Fang Z, Yang Y. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways. J Ethnopharmacol 2021;279:114350. [PMID: 34157326 DOI: 10.1016/j.jep.2021.114350] [Reference Citation Analysis]
212 Dawood AA, Saleh AA, Elbahr O, Gohar SF, Habieb MS. Inverse relationship between the level of miRNA 148a-3p and both TGF-β1 and FIB-4 in hepatocellular carcinoma. Biochem Biophys Rep 2021;27:101082. [PMID: 34355070 DOI: 10.1016/j.bbrep.2021.101082] [Reference Citation Analysis]
213 Chen M, Li J, Shu G, Shen L, Qiao E, Zhang N, Fang S, Chen X, Zhao Z, Tu J, Song J, Du Y, Ji J. Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01385-x] [Reference Citation Analysis]
214 Zhang Y, Tan Y, Liu S, Yin H, Duan J, Fan L, Zhao X, Jiang B. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol Mech Methods 2022;:1-9. [PMID: 35592903 DOI: 10.1080/15376516.2022.2075297] [Reference Citation Analysis]
215 Yang S, Cheng Y, Wang X, Wei P, Wang H, Tan S. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy. Front Genet 2021;12:777931. [PMID: 34899862 DOI: 10.3389/fgene.2021.777931] [Reference Citation Analysis]
216 Guijarro LG, Sanmartin-Salinas P, Pérez-Cuevas E, Toledo-Lobo MV, Monserrat J, Zoullas S, Sáez MA, Álvarez-Mon MA, Bujan J, Noguerales-Fraguas F, Arilla-Ferreiro E, Álvarez-Mon M, Ortega MA. Actinomycin D Arrests Cell Cycle of Hepatocellular Carcinoma Cell Lines and Induces p53-Dependent Cell Death: A Study of the Molecular Mechanism Involved in the Protective Effect of IRS-4. Pharmaceuticals (Basel) 2021;14:845. [PMID: 34577545 DOI: 10.3390/ph14090845] [Reference Citation Analysis]
217 Zhang H, Liu R, Sun L, Guo W, Hu X. The Effect of Ferroptosis-Related Genes on Prognosis and Tumor Mutational Burden in Hepatocellular Carcinoma. J Oncol 2021;2021:7391560. [PMID: 34457006 DOI: 10.1155/2021/7391560] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Nie Y, Jiang MC, Liu C, Liu Q, Zhu X. CXCL5 Has Potential to Be a Marker for Hepatocellular Carcinoma Prognosis and Was Correlating With Immune Infiltrates. Front Oncol 2021;11:637023. [PMID: 33869023 DOI: 10.3389/fonc.2021.637023] [Reference Citation Analysis]
219 Guerrero L, Paradela A, Corrales FJ. Development of a Standardized MRM Method for the Quantification of One Carbon Metabolism Enzymes. Methods Mol Biol 2022;2420:159-75. [PMID: 34905173 DOI: 10.1007/978-1-0716-1936-0_13] [Reference Citation Analysis]
220 Lei P, Chen H, Feng C, Yuan X, Xiong Z, Liu Y, Liao W. Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy. ACS Nano 2022. [PMID: 35005889 DOI: 10.1021/acsnano.1c08477] [Reference Citation Analysis]
221 Hu X, Li R, Li Q, Zang M, Yuan G, Chen J. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. BMC Infect Dis 2022;22:614. [PMID: 35836207 DOI: 10.1186/s12879-022-07602-0] [Reference Citation Analysis]
222 Li P, Shi Y, Zhao B, Xu W, Xu Z, Zhang J, Guo Z, Bi Y, Wang T, Qin Y, Wang T. Pharmacological evaluation and mechanistic study of compound Xishu Granule in hepatocellular carcinoma. Journal of Traditional Chinese Medical Sciences 2020;7:255-64. [DOI: 10.1016/j.jtcms.2020.07.006] [Reference Citation Analysis]
223 Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 2021;18:45-56. [PMID: 33041338 DOI: 10.1038/s41423-020-00558-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
224 Lv C, Li XJ, Hao LX, Zhang S, Song Z, Ji XD, Gong B. Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma. Clin Transl Oncol 2021. [PMID: 34282556 DOI: 10.1007/s12094-021-02673-y] [Reference Citation Analysis]
225 Sheng R, Huang J, Zhang W, Jin K, Yang L, Chong H, Fan J, Zhou J, Wu D, Zeng M. A Semi-Automatic Step-by-Step Expert-Guided LI-RADS Grading System Based on Gadoxetic Acid-Enhanced MRI. J Hepatocell Carcinoma 2021;8:671-83. [PMID: 34235105 DOI: 10.2147/JHC.S316385] [Reference Citation Analysis]
226 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
227 Zhou X, Chi Y, Dong Z, Tao T, Zhang X, Pan W, Wang Y. A nomogram combining PPARγ expression profiles and clinical factors predicts survival in patients with hepatocellular carcinoma. Oncol Lett 2021;21:319. [PMID: 33692851 DOI: 10.3892/ol.2021.12581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Yoo GS, Yu JI, Park HC. Current role of proton beam therapy in patients with hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:175-82. [DOI: 10.18528/ijgii210043] [Reference Citation Analysis]
229 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 29.0] [Reference Citation Analysis]
230 Wang L, Zhang W, Yang T, He L, Liao Y, Lu J. Construction and Comprehensive Analysis of a Stratification System Based on AGTRAP in Patients with Hepatocellular Carcinoma. Dis Markers 2021;2021:6144476. [PMID: 34840632 DOI: 10.1155/2021/6144476] [Reference Citation Analysis]
231 Liu S, Yang L, Jia S, Zhao R, Jin Z. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma. Int Immunopharmacol 2021;100:108161. [PMID: 34555643 DOI: 10.1016/j.intimp.2021.108161] [Reference Citation Analysis]
232 Shankar N, Ramani A, Griffin C, Agbim U, Kim D, Ahmed A, Asrani SK. Extrahepatic causes of death in cirrhosis compared to other chronic conditions in the United States, 1999-2017. Ann Hepatol 2021;26:100565. [PMID: 34728419 DOI: 10.1016/j.aohep.2021.100565] [Reference Citation Analysis]
233 Hauth F, Roberts HJ, Hong TS, Duda DG. Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers. Int J Mol Sci 2022;23:1926. [PMID: 35216045 DOI: 10.3390/ijms23041926] [Reference Citation Analysis]
234 Chuang KT, Wang SN, Hsu SH, Wang LT. Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity. Cancer Med 2021;10:5545-56. [PMID: 34173348 DOI: 10.1002/cam4.4094] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Zhu C, Xiao H, Jiang X, Tong R, Guan J. Prognostic Biomarker DDOST and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma. Front Genet 2022;12:819520. [DOI: 10.3389/fgene.2021.819520] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
236 Gong Y, Li D, Li L, Yang J, Ding H, Zhang C, Wen G, Wu C, Fang Z, Hou S, Yang Y. Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis. Food and Chemical Toxicology 2021;147:111912. [DOI: 10.1016/j.fct.2020.111912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
237 Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, Dalekos GN. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers (Basel) 2021;13:3510. [PMID: 34298722 DOI: 10.3390/cancers13143510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Caviglia GP, Troshina G, Santaniello U, Rosati G, Bombaci F, Birolo G, Nicolosi A, Saracco GM, Ciancio A. Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers 2022;14:828. [DOI: 10.3390/cancers14030828] [Reference Citation Analysis]
239 Liu C, Liu H, Dasgupta M, Hellman LM, Zhang X, Qu K, Xue H, Wang Y, Fan F, Chang Q, Yu D, Ge L, Zhang Y, Cui Z, Zhang P, Heller B, Zhang H, Shi B, Baker BM, Liu C. Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma. Sci Rep 2022;12:12068. [PMID: 35840635 DOI: 10.1038/s41598-022-15946-5] [Reference Citation Analysis]
240 Tan JL, Sidhu-Brar S, Woodman R, Chinnaratha MA. Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis. J Gastrointest Cancer 2022. [PMID: 35717551 DOI: 10.1007/s12029-022-00842-y] [Reference Citation Analysis]
241 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
242 Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, Zhang Z, Xie J, Wang C, Chen D, Huang Y, Wei X, Shi Y, Zhao Z, Li Y, Guo Z, Yu Q, Xu L, Volpe G, Qiu S, Zhou J, Ward C, Sun H, Yin Y, Xu X, Wang X, Esteban MA, Yang H, Wang J, Dean M, Zhang Y, Liu S, Yang X, Fan J. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021;184:404-421.e16. [PMID: 33357445 DOI: 10.1016/j.cell.2020.11.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
243 Liu F, Liang J, Long P, Zhu L, Hou W, Wu X, Luo C. ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:799566. [PMID: 35071004 DOI: 10.3389/fonc.2021.799566] [Reference Citation Analysis]
244 Luo M, Lin Y, Liang R, Li Y, Ge L. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. J Inflamm Res 2021;14:4217-28. [PMID: 34483677 DOI: 10.2147/JIR.S324336] [Reference Citation Analysis]
245 Zaizen Y, Nakano M, Fukumori K, Yano Y, Takaki K, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Kuromatsu R, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T. Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:5282. [PMID: 34771452 DOI: 10.3390/cancers13215282] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Ren P, Wang K, Ma J, Cao X, Zhao J, Zhao C, Guo Y, Ye H. Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer. JHC 2022;Volume 9:221-32. [DOI: 10.2147/jhc.s352057] [Reference Citation Analysis]
247 Guan MC, Ouyang W, Wang MD, Liang L, Li N, Fu TT, Shen F, Lau WY, Xu QR, Huang DS, Zhu H, Yang T. Biomarkers for hepatocellular carcinoma based on body fluids and feces. World J Gastrointest Oncol 2021; 13(5): 351-365 [PMID: 34040698 DOI: 10.4251/wjgo.v13.i5.351] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
248 Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, Li Z, Wang L, Bi X, Zhao H, Liu K. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 2021;15:621-9. [PMID: 33826043 DOI: 10.1007/s12072-021-10171-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
249 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
250 Fu X, Li X, Han D, Yang W, Liu C, Fan L, Ding S, Ma Y. Ultrasensitive electrochemical biosensor for des-gamma-carboxy prothrombin analysis based on core-shell Pd@PtCu-alloy loaded on WS2 nanosheet. Journal of Electroanalytical Chemistry 2021;888:115213. [DOI: 10.1016/j.jelechem.2021.115213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Salehi S, Tavabie OD, Villanueva A, Watson J, Darling D, Quaglia A, Farzaneh F, Aluvihare VR. Regeneration linked miRNA modify tumor phenotype and can enforce multi-lineage growth arrest in vivo. Sci Rep 2021;11:10538. [PMID: 34006907 DOI: 10.1038/s41598-021-90009-9] [Reference Citation Analysis]
252 Sheng R, Zeng M, Jin K, Zhang Y, Wu D, Sun H. MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. Acad Radiol 2022;29:819-29. [PMID: 34649778 DOI: 10.1016/j.acra.2021.09.004] [Reference Citation Analysis]
253 Zhang C, Lu L, Xin H, Zhang M, Ding Z, Li Q, Chen K, Hu M, Liu S, Li N, Mei J. The HBV Specially-Related Long Noncoding RNA HBV-SRL Involved in the Pathogenesis of Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/9034105] [Reference Citation Analysis]
254 Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, Xu QR, Huang DS, Shen F, Zhu H, Yang T. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021; 13(4): 197-215 [PMID: 33889272 DOI: 10.4251/wjgo.v13.i4.197] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
256 Ragusa F, Panera N, Cardarelli S, Scarsella M, Bianchi M, Biagioni S, Giorgi M, Alisi A, Massimi M. Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2182. [PMID: 34062786 DOI: 10.3390/cancers13092182] [Reference Citation Analysis]
257 Ahmad M, Dhasmana A, Harne PS, Zamir A, Hafeez BB. Chemokine Clouding and Liver Cancer Heterogeneity: Does it Impact Clinical Outcomes? Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.015] [Reference Citation Analysis]
258 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
259 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
260 Nishida N. Metabolic disease as a risk of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:87-90. [PMID: 33317238 DOI: 10.3350/cmh.2020.0302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
261 Bainrauch A, Šisl D, Markotić A, Ostojić A, Gašparov S, Bralić Lang V, Kovačić N, Grčević D, Mrzljak A, Kelava T. NOTCH3 rs1043996 Polymorphism Is Associated with the Occurrence of Alcoholic Liver Cirrhosis Independently of PNPLA3 and TM6SF2 Polymorphisms. J Clin Med 2021;10:4621. [PMID: 34640639 DOI: 10.3390/jcm10194621] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]